Keywords: Merck & Co, Ariad Pharma, Ridaforolimus, Taltorvic, Sarcoma, USA, FDA, CRL

FDA calls for more trials on Merck & Co and Ariad's sarcoma drug ridaforolimus

Article | 06 June 2012

Print This

US drug giant Merck & Co (NYSE: MRK) has received a complete response letter from the US Food and Drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in